Home/Filings/4/0001127602-18-014165
4//SEC Filing

Ratliff John D 4

Accession 0001127602-18-014165

CIK 0000920148other

Filed

Apr 4, 8:00 PM ET

Accepted

Apr 5, 10:14 AM ET

Size

5.6 KB

Accession

0001127602-18-014165

Insider Transaction Report

Form 4
Period: 2018-04-03
Ratliff John D
CEO, Covance Drug Development
Transactions
  • Award

    Restricted Stock Unit

    2018-04-03+12,12026,337 total
    Common Stock (12,120 underlying)
Footnotes (3)
  • [F1]Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock.
  • [F2]The Restricted Stock Units will vest in three installments as follows: 20% of the Restricted Stock Units will vest on April 3, 2019; 30% of the Restricted Stock Units will vest on April 3, 2020; and 50% of the Restricted Stock Units will vest on April 3, 2021.
  • [F3]This number reflects the aggregate number of Restricted Stock Units held by the reporting person.

Issuer

LABORATORY CORP OF AMERICA HOLDINGS

CIK 0000920148

Entity typeother

Related Parties

1
  • filerCIK 0001575951

Filing Metadata

Form type
4
Filed
Apr 4, 8:00 PM ET
Accepted
Apr 5, 10:14 AM ET
Size
5.6 KB